



## Publikationer

### 2009

Salzer J, Svenningsson A, Sundström P  
Season of Birth and Multiple Sclerosis in Sweden.  
*Acta Neur Scand* 2009 (in press)

Martola J, Bergström J, Fredrikson S, Stawiarz L, Hillert J, Zhang Y, Flodmark O, Lilja A, Ekbom A, Aspelin P, Kristoffersen Wiberg M  
A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1 D, 2 D and volumetric measurements from MRI-images.  
*Neuroradiology* 2009 (accepted for publication, Aug. 2009, NRAD-D-09-00144R1)

Hedström AK, Bäärnhielm M, Olsson T, Alfredsson L.  
Tobacco smoking, but not Swedish snuff use, increases the risk of multiple sclerosis.  
*Neurology* 2009 Sep 1;73(9):696-701.

Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergstrom J, Flodmark O, Aspelin P, Kristoffersen Wiberg M.  
One-Dimensional-Ratio Measures of Atrophy Progression in Multiple Sclerosis as Evaluated by Longitudinal Magnetic Resonance Imaging.  
*Acta Radiol.* 2009 Jul 28;1-9.

Bahmanyar S, Montgomery SM, Hillert J, Ekbom A, Olsson T.  
Cancer risk among patients with multiple sclerosis and their parents.  
*Neurology* 2009 Mar 31;72(13):1170-7.

Holmén C, Piehl F, Hillert J, Olsson T.  
The “Immunomodulation and Multiple Sclerosis Epidemiology” (IMSE) study; A Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of natalizumab (Tysabri).  
*Abstract, ECTRIMS in Düsseldorf 2009*

Eva J. Greiner, Jan Hillert and the Swedish MS Registry  
Effects of mitoxantrone treatment on different multiple sclerosis courses as documented in the Swedish multiple sclerosis registry  
*Abstract, ECTRIMS in Düsseldorf 2009*

Lundkvist M, Fogdell-Hahn A, Hillert J  
Multiple sclerosis patients lacking antibodies in cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon-beta.” publiceras i ett supplement till tidskriften  
*Abstract publiceras i ett supplement till tidskriften Multiple Sclerosis september 2009*

### 2008

Thangarajh M, Gomez-Rial J, Hedström AK, Hillert J, Alvarez-Cermeño JC, Masterman T, Villar LM  
Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis.  
*Mult Scler.* 2008 Nov;14(9):1208-13.



Flensner G, Ek AC, Landtblom AM, Söderhamn O.  
Fatigue in relation to perceived health: people with multiple sclerosis compared with people in the general population.  
*Scand J Caring Sci.* 2008 Sep;22(3):391-400.

Kobelt G, Berg J, Lindgren P, Jonsson B, Stawiarz L, Hillert J.  
Modeling the Cost-Effectiveness of a New Treatment for MS (natalizumab) compared to Current Standard Practice in Sweden (An indirect comparison of a clinical trial with natalizumab with data from the Swedish MS Registry)  
*Multiple Sclerosis*, 2008 Jun;14(5):679-9

Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergström J, Flodmark O, Aspelin P, Kristoffersen Wiberg M.  
Rate of ventricular enlargement in multiple sclerosis: a nine-year multiple resonance imaging follow-up study.  
*Acta Radiologica*, 2008 Jun;49(5):570-9

Karin Eliaeson, IVL, Marcus Liljeberg, IVL, Anders Björk, IVL, Ingrid Kockum, KI, Alasdair Skelton, SU, Eva-Jirner Lindström, SGU  
Relationships of geochemistry and multiple sclerosis  
*IVL Svenska Miljöinstitutets rapport, B1824 December 2008*

Rikard Carlsson, apoteksstuderande, examensarbete:  
Evaluation of the first year of natalizumab treatment of MS: a retrospective study at the MS Center, Sahlgrenska University Hospital, Gothenburg.  
*Master Thesis in Pharmacy 2008, handledare Jan Lycke*

Kristina Yilmaz, apoteksstuderande, examensarbete:  
Multiple sclerosis treatment with mitoxantrone: A retrospective study of patient selection, efficacy, and safety at the Department of Neurology, Sahlgrenska University Hospital .  
*Master Thesis in Pharmacy 2008, handledare Jan Lycke*

Jenny Silversparre, apoteksstuderande, examensarbete:  
Treatment of multiple sclerosis with interferon beta: a retrospective study of the risk to develop neutralizing antibodies.  
*Master Thesis in Pharmacy 2008, handledare Jan Lycke*

## **2007**

Tedeholm H, Skoog B, Hillert J, Runmarker B, Stawiarz L, Andersen O.  
Att optimera historiska kontroller. Utvärdering av långtidseffekter av MS-behandling med "virtual placebo". En studie av MS naturalförlopp.  
*Läkartidningen.* 2007 May 30-Jun 3;104(22):1684-8

Smestad C, Brynedal B, Jonasdottir G, Lorentzen AR, Masterman T, Akesson E, Spurkland A, Lie BA, Palmgren J, Celius EG, Hillert J, Harbo HF.  
The impact of HLA-A and -DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients.  
*Eur J Neurol.* 2007 Aug;14(8):835-40.



Lundmark F, Salter H, Hillert J.

An association study of two functional promotor polymorphisms in the myeloperoxidase (MPO) gene in multiple sclerosis.

*Mult Scler.* 2007 Jul;13(6):697-700

Nilsagård Y, Fedeli C, Gunnarsson L-G, Denison E.

Clinical relevance using timed walk tests and 'timed up and go' testing in persons with Multiple Sclerosis. Reproducibility, correlations, and smallest percentage to detect genuine change.

*Physiotherapy Research International* 2007;12(2): 105-114.

Martola J, Stawiarz L, Fredrikson S, Hillert J, Bergström J, Flodmark O, Kristoffersen-Wiberg M. Progression of non-age related callosal brain atrophy in multiple sclerosis. A nine years longitudinal MRI study representing four decades of disease development,

*J Neurol Neurosurg Psychiatry.* 2007 Apr; 78(4):375-80.

Nilsagård Y, Gunnarsson L-G, Deinsion E.

Self-perceived limitations of gait in persons with Multiple Sclerosis.

*Advances in Physiotherapy* 2007; 9(3):136-143.

## **2006**

Imrell K, Landtblom AM, Hillert J, Masterman T.

Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct.

*Neurology* (2006) 67:1062-4.

Holmqvist P, Wallberg M, Hammar M, Landtblom AM, Brynhildsen J.

Symptoms of multiple sclerosis in women in relation to sex steroid exposure.

*Maturitas.* 2006 May 20;54(2):149-53.

Nilsagård Y, Denison E, Gunnarsson L-G.

Evaluation of a single session with cooling garment for persons with multiple sclerosis - a randomized trial.

*Disability and Rehabilitation* 2006;1(4):225-233.

## **2005**

Flensner G., Ek A-C., Söderhamn O.

Reliability and validity of the Swedish version of the Fatigue Impact scale (FIS).

*Scandinavian Journal of Occupational Therapy*, 2005, 12: 170-180.

Flensner G.

Fatigue in individuals with Multiple Sclerosis. Lived experiences and perceived impact in daily life. *Linköping University, Medical Dissertation No 917, Department of Medicine and Care, Division of Nursing Science, Faculty of Health Sciences, Linköping University, 2005.*

En beskrivning av SMS-registret finns i den nya upplagan av "Multipel skleros - Metodpärm" som tryckts i en första upplaga på ett par hundra exemplar och som nu 2005 finns tillgänglig på Svenska MS-Sällskapetets hemsida.



## 2004

Landtblom AM, Flensner G, Callander M, Stawiarz L.

The Swedish MS registry points out an important clinical problem: physical and psychological fatigue is a main symptom in multiple sclerosis.

*Läkartidningen. 2004 Oct 28; 101(44):3456-7.*

Inger Boström, sjuksköterska, Kristinehamn, "Är Värmland ett högriskområde för multipel skleros?". *Magisterarbete som lagts fram 20 Sept. 2004, Nordiska Vårdhögskolan, Göteborg. Handledare AM Landtblom, Max Petzold.*

Khademi M, Illes Z, Gielen AW, Marta M, Takazawa N, Baecher-Allan C, Brundin L, Hannerz J, Martin C, Harris RA, Hafler DA, Kuchroo VK, Olsson T, Piehl F, Wallstrom E. T Cell Ig- and mucin-domain-containing molecule-3 (TIM-3) and TIM-1 molecules are differentially expressed on human Th1 and Th2 cells and in cerebrospinal fluid-derived mononuclear cells in multiple sclerosis.

*J Immunol. 2004 Jun 1;172(11):7169-76.*

Guggenmos J, Schubart AS, Ogg S, Andersson M, Olsson T, Mather IH, Linington C.

Antibody cross-reactivity between myelin oligodendrocyte glycoprotein and the milk protein butyrophilin in multiple sclerosis.

*J Immunol. 2004 Jan 1;172(1):661-8.*

## 2003

Data ur SMS-registret diskuterades i två debattartiklar i läkartidningen våren 2003 av Jan Fagius respektive Jan Hillert. "Sjukdomsmodifierande behandling mot MS - framsteg med komplikationer" (jämte) Replik: "Problemet är under behandlingen!" av Jan Hillert (deb) 2003 nr 13 sid 1164-8.

Maria Turesson, med. kand., uppsats "Evidens-baserad Interferon-behandling i teori och praktik". Redovisades den 2/6 2003 (SMS-registret var delvis använt för att undersöka hur neurolog mottagning i Lund följer Läkemedelsverkets rekommendationer för interferon-behandling).

Gielen A, Khademi M, Muhallab S, Olsson T, Piehl F.

Increased brain-derived neurotrophic factor expression in white blood cells of relapsing-remitting multiple sclerosis patients.

*Scand J Immunol. 2003 May;57(5):493-7.*

Danilov AI, Andersson M, Bavand N, Wiklund NP, Olsson T, Brundin L.

Nitric oxide metabolite determinations reveal continuous inflammation in multiple sclerosis.

*J Neuroimmunol. 2003 Mar; 136(1-2):112-8.*